Literature DB >> 16736884

Management of cardiac device infections: A retrospective survey of a non-surgical approach combining antibiotic therapy with transvenous removal.

C Tascini1, M G Bongiorni, G Gemignani, E Soldati, A Leonildi, G Arena, R Doria, G Giannola, F La Pira, E Tagliaferri, P Caravelli, R Dell'Anna, F Menichetti.   

Abstract

Pacemakers (PMs) and implantable cardioverter defibrillators (ICDs) have become life-saving therapeutic tools for patients with cardiac arrhythmia. Complications include thrombosis, embolism and infections at a highly variable rate. Surgical removal of the infected device has been perceived as the only way to guarantee a successful outcome and to reduce the high risk of mortality. Recently, a transvenous extraction method has been developed to remove infected intracardiac leads without sternotomy. This survey was designed to evaluate the outcome of an approach combining antibiotic therapy with non-surgical transvenous complete removal for the management of cardiac device infections (CDIs). We reviewed case-histories of 121 patients (105 with PM and 16 with ICD infections). The aim of our retrospective survey was to ascertain that a non-invasive transvenous complete removal of the infected devices is safe and effective when associated with appropriate antibiotic therapy starting 10 days before the procedure and extending to at least three weeks after. The infected devices were successfully removed in all patients with a non-surgical transvenous technique. The infections were most frequently caused by coagulase-negative staphylococci (70%), Staphylococcus aureus (14%), and Gram-negative rods (12%). Polymicrobial infections were documented in 19 patients and represent 16% of all device-related infections. The removal of the devices was done during antibiotic therapy, administered for a median of 26 days (range 23 to 45 days). Neither fatalities nor relapse of infections were recorded in the patient population during the one-year follow-up visits. According to our experience, CDIs can be treated with antibiotic therapy and non-surgical removal of the entire infected device, thus allowing a successful reimplantation. This procedure prevents recurrent infections and operative mortality.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16736884     DOI: 10.1179/joc.2006.18.2.157

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  5 in total

1.  Thirteen square centimetre mass causing syncope in a patient with device related infective endocarditis.

Authors:  Sergio Barra; Flavia Semedo; Rui Providencia; Carlos Pinto
Journal:  BMJ Case Rep       Date:  2011-12-08

Review 2.  Micafungin for Candida albicans pacemaker-associated endocarditis: a case report and review of the literature.

Authors:  Carlo Tascini; Maria Grazia Bongiorni; Enrico Tagliaferri; Antonello Di Paolo; Sarah Flammini; Ezio Soldati; Alessandro Leonildi; Andrea Di Cori; Francesco Menichetti
Journal:  Mycopathologia       Date:  2012-10-17       Impact factor: 2.574

3.  Combination prophylactic therapy with rifampin increases efficacy against an experimental Staphylococcus epidermidis subcutaneous implant-related infection.

Authors:  Alexandra I Stavrakis; Jared A Niska; Jonathan H Shahbazian; Amanda H Loftin; Romela Irene Ramos; Fabrizio Billi; Kevin P Francis; Michael Otto; Nicholas M Bernthal; Daniel Z Uslan; Lloyd S Miller
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

4.  Timing of device reimplantation and reinfection rates following cardiac implantable electronic device infection: a systematic review and meta-analysis.

Authors:  Derek Chew; Ranjani Somayaji; John Conly; Derek Exner; Elissa Rennert-May
Journal:  BMJ Open       Date:  2019-09-03       Impact factor: 2.692

Review 5.  Successful management of multiple permanent pacemaker complications--infection, 13 year old silent lead perforation and exteriorisation following failed percutaneous extraction, superior vena cava obstruction, tricuspid valve endocarditis, pulmonary embolism and prosthetic tricuspid valve thrombosis.

Authors:  Pankaj Kaul; Krishna Adluri; Kalyana Javangula; Wasir Baig
Journal:  J Cardiothorac Surg       Date:  2009-02-24       Impact factor: 1.637

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.